STOCK TITAN

Lipocine (LPCN) SEC Filings, Jun 23, 2025

LPCN NASDAQ

Lipocine Inc.’s SEC filings document the regulatory record for a clinical-stage biopharmaceutical company focused on oral drug-delivery products. Recent 8-K filings furnish financial results, operational updates, corporate presentations and clinical disclosures for LPCN 1154 in postpartum depression, along with information on TLANDO licensing and royalty-related business activity.

The company’s filings also cover governance and capital-structure matters. Proxy materials describe annual meeting voting matters and board oversight, while current reports document board composition changes and common-stock offering documentation connected to an equity distribution arrangement. These filings frame Lipocine’s pipeline development, commercialization agreements, financing tools, risk disclosures and public-company governance.

Form 8-K
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-4.85%
Tags
current report

FAQ

How many Lipocine (LPCN) SEC filings are available on StockTitan?

StockTitan tracks 71 SEC filings for Lipocine (LPCN), including 10-K annual reports, 10-Q quarterly reports, 8-K current reports, and Form 4 insider trading disclosures. Each filing includes AI-generated summaries, impact scoring, and sentiment analysis.

When was the most recent SEC filing for Lipocine (LPCN)?

The most recent SEC filing for Lipocine (LPCN) was filed on November 13, 2026.